MedTrace Logo

Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography

NCT01124019 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2019-03-07

No results posted yet for this study

Summary

The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can improve the positive value of breast biopsies in women with BIRADS 4 mammograms.

Conditions

  • Mammography

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Susan Domchek, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01124019 on ClinicalTrials.gov